UmarFarooqMD

PubMed

• 90 citations
  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
  Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis
  Blood. 2023-05-11
• 3 citations
  T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
  Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, Brian J Smith, Caitlin D Lemke-Miltner
  Blood. 2024-05-02
• 9 citations
  JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma.
  Jaroslav Zak, Isaraphorn Pratumchai, Brett S Marro, Kristi L Marquardt, Reza Beheshti Zavareh
  Science. 2024-06-21

Abstracts/Posters

• Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all